The main risk is still validation, not survival. Rigetti has enough liquidity to keep building, but the equity case needs accepted deployments, better performance, and evidence that customers pay for trusted access rather than just experiments. If
decoherence, delays, or rival benchmarks win the narrative, the market can compress the multiple long before revenue matures.